Drug Trial Radar · NCT05126992
EU Secondary Data Post-Authorisation Safety Study of AZD1222
Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,321,930
Actual
Start
Feb 18, 2022
Primary completion
Jan 24, 2024
Study completion Jan 24, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- RTI Health Solutions
- First posted
- Nov 19, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting. A cohort and a self-controlled case series desings will be used.
Conditions
- COVID-19, Vaccine Adverse Events of Special Interest
Interventions
AZD1222Biological
Covid-19 AstraZeneca Vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events of special interestTime frame: up to 365 days
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Utrecht, Netherlands
Research Site
Barcelona, Spain
Research Site
Valencia, Spain
Research Site
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.